Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
November 24, 2025Pamplona/MadridIn recruitment
NOVOFFOX Trial of tumor treatment fields (TTFields, 150 kHz) concomitant with modFOLFIRINOX for the first-line treatment of metastatic pancreatic adenocarcinoma (NOVOFFOX).
The aim of this study is to evaluate the efficacy and safety of TTFields in combination with the chemotherapy you will receive for your cancer (oxaliplatin-irinotecan-fluorouracil, FOLFIRINOX). -
November 19, 2025Pamplona/MadridIn recruitment
M22-132 Ensayo de Epcoritamab en combinación con antineoplásicos en pacientes con linfoma no Hodgkin [SP]
The purpose of this study is to evaluate a drug called Epcoritamab in combination with other drugs used to treat non-Hodgkin lymphoma (NHL). Epcoritamab may work better when combined with other drugs that treat cancer in different ways. -
November 19, 2025Pamplona/MadridIn recruitment
MK-2870-004 Randomized, open-label, phase 3 clinical trial of MK-2870 in previously treated non-small cell lung cancer with EGFR mutations or other genomic alterations.
El objetivo principal de este estuido es comparar MK-2870 con la quimioterapia con respecto a la SLP según RECIST 1.1 evaluada por evaluada por BICR en CPNM con mutaciones del EGFR mutaciones. -
November 19, 2025Pamplona/MadridIn recruitment
-
November 18, 2025PamplonaIn recruitmentEarly phase
FS222-19101 Trial to evaluate the safety and antitumor activity of FS222, a bispecific antibody against CD137/PD-L1, in subjects with advanced malignant neoplasms
The objective is to determine whether FS222 is safe in the treatment of cancer and the extent to which a person tolerates side effects. -
November 7, 2025Pamplona/MadridIn recruitmentEarly phase
GS-US-570-6015 [SP]
The objective or purpose of this clinical trial is to test an experimental drug called GS-1811 alone, GS-1811 in combination with zimberelimab (also known as AB122 or GS-0122), and zimberelimab alone for the treatment of different types of cancer. -
November 4, 2025Pamplona/MadridIn recruitment
GS-US-626-6216 Clinical trial to evaluate zimberelimab and domvanalimab in combination with chemotherapy versus pembrolizumab with chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer.
The main goal of this study is to determine whether ZIM alone or in combination with DOM and chemotherapy is safe and effective when given to patients with the type of cancer you have. The first standard treatment approved for metastatic NSCLC without gene alterations is anti-PD-(L)1 immunotherapy, which is a drug that helps the immune system target cancer cells for destruction, combined with or without platinum-based chemotherapy. The study will also attempt to understand how the combination of... -
October 27, 2025PamplonaIn recruitment
AB18001 Clinical trial to evaluate the safety, pharmacokinetics, and efficacy of daily intravenous administration of AB8939 in patients with relapsed/refractory acute myeloid leukemia
The aim of this study is to determine the efficacy and safety of the investigational drug AB8939 in patients with relapsed or refractory acute myeloid leukemia or refractory myelodysplastic syndrome. -
October 27, 2025PamplonaIn recruitmentEarly phase
1438-0001 Clinical trial to evaluate different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3
The aim of this study is to determine the most appropriate dose of BI 764532 that patients with cancer like yours who have progressed after treatment with available standard therapies, including platinum therapy, or who are not eligible for available standard therapies, will receive in the future. Only patients confirmed to be positive for a tumor marker called "DLL3" will be eligible for treatment with BI 764532 in this study. -
October 22, 2025Pamplona/MadridIn recruitmentEarly phase